Manouchehr Khazandi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Manouchehr Khazandi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Darren J. Trott
Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, Australia
4 shared publications - Stephen W. Page
Neoculi Pty Ltd., Burwood, VIC 3125, Australia
3 shared publications - Abiodun David Ogunniyi
School of Animal and Veterinary Sciences, Adelaide University, Roseworthy, South Australia 5371, Australia
2 shared publications - Adam McCluskey
Chemistry, School of Environmental and Life Science, The University of Newcastle, University Drive, Callaghan, NSW, 2308, Australia
2 shared publications - Andrew Stevens
School of Environmental & Life Sciences The University of Newcastle University Drive Callaghan NSW 2308 Australia
2 shared publications - Cecilia C. Russell
Chemistry, School of Environmental & Life Sciences The University of Newcastle University Drive Callaghan NSW 2308 Australia
2 shared publications
Latest Publications
- 1 November 2021
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 138, 104893
Advances in understanding the specificity function of transporters by machine learning
- 1 November 2021
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 138, 104893
Advances in understanding the specificity function of transporters by machine learning
- Open Access
- 4 July 2019
- Published by Wiley in ChemistryOpen
- Vol. 8 (7) , 896-907
Discovery of 4,6‐bis(2‐((E)‐benzylidene)hydrazinyl)pyrimidin‐2‐Amine with Antibiotic Activity
Robenidine (E)‐N′‐((E)‐1‐(4‐chlorophenyl)ethylidene)‐2‐(1‐(4‐chlorophenyl)ethylidene)hydrazine‐1‐carboximidhydrazide displays methicillin‐resistant Staphyoccoccus aureus (MRSA) and vancomycin‐resistant Enterococci (VRE) MICs of 2 μg mL−1. Herein we describe the structure‐activity relationship development of a novel series of guanidine to 2‐aminopyrimidine isosteres that ameliorate the low levels of mammalian cytotoxicity in the lead compound while retaining good antibiotic activity. Removal of the 2‐NH2 pyrimidine moiety renders these analogues inactive. Introduction of a central 2‐NH2 triazine moiety saw a 10‐fold activity reduction. Phenyl to cyclohexyl isosteres were inactive. The 4‐BrPh and 4‐CH3Ph with MIC values of 2 and 4 μg mL−1, against MRSA and VRE respectively, are promising candidates for future development.
- 4 July 2019
- Published by Wiley in ChemistryOpen
- Vol. 8 (7) , 896-907
Open AccessDiscovery of 4,6‐bis(2‐((E)‐benzylidene)hydrazinyl)pyrimidin‐2‐Amine with Antibiotic Activity
Robenidine (E)‐N′‐((E)‐1‐(4‐chlorophenyl)ethylidene)‐2‐(1‐(4‐chlorophenyl)ethylidene)hydrazine‐1‐carboximidhydrazide displays methicillin‐resistant Staphyoccoccus aureus (MRSA) and vancomycin‐resistant Enterococci (VRE) MICs of 2 μg mL−1. Herein we describe the structure‐activity relationship development of a novel series of guanidine to 2‐aminopyrimidine isosteres that ameliorate the low levels of mammalian cytotoxicity in the lead compound while retaining good antibiotic activity. Removal of the 2‐NH2 pyrimidine moiety renders these analogues inactive. Introduction of a central 2‐NH2 triazine moiety saw a 10‐fold activity reduction. Phenyl to cyclohexyl isosteres were inactive. The 4‐BrPh and 4‐CH3Ph with MIC values of 2 and 4 μg mL−1, against MRSA and VRE respectively, are promising candidates for future development.
- 19 November 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (23) , 2573-2580
Gram‐Positive and Gram‐Negative Antibiotic Activity of Asymmetric and Monomeric Robenidine Analogues
Desymmetrisation of robenidine (1: N′,2‐bis((E)‐4‐chlorobenzylidene)hydrazine‐1‐carboximidhydrazide) and the introduction of imine alkyl substituents gave good antibiotic activity. Of note was the increased potency of two analogues against vancomycin‐resistant Enterococci (VRE), one of which returned a MIC of 0.5 μg mL−1. Five analogues were found to be equipotent or more potent than the lead 1. Introduction of an indole moiety resulted in the most active robenidine analogue against methicillin‐resistant S. aureus (MRSA), with a MIC of 1.0 μg mL−1. Imine C=NH isosteres (C=O/C=S) were inactive. Monomeric analogues were 16–64 μg mL−1 active against MRSA and VRE. An analogue that lacks the terminal hydrazide NH moiety showed modest Gram‐negative activity at 64 μg mL−1. A 4‐tert‐butyl analogue was shown to be active against both Gram‐positive and ‐negative strains at 16–64 μg mL−1. In general, additional modifications with aromatic moieties was poorly tolerated, except with concomitant introduction of an imine C‐alkyl group. The activity of these analogues against MRSA and VRE ranged from 8 μg mL−1 to inactive (MIC>128 μg mL−1) with the naphthyl and indole analogues. Gram‐negative activity was most promising with two compounds at 16 μg mL−1 against E. coli. Against P. aeruginosa, the highest activity observed was with MIC values of 32 μg mL−1 with another two analogues. Combined, these findings support the further development of the (E)‐2‐benzylidenehydrazine‐1‐carboximidamide scaffold as a promising scaffold for the development of antibiotics against Gram‐positive and Gram‐negative strains.
- 19 November 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (23) , 2573-2580
Gram‐Positive and Gram‐Negative Antibiotic Activity of Asymmetric and Monomeric Robenidine Analogues
Desymmetrisation of robenidine (1: N′,2‐bis((E)‐4‐chlorobenzylidene)hydrazine‐1‐carboximidhydrazide) and the introduction of imine alkyl substituents gave good antibiotic activity. Of note was the increased potency of two analogues against vancomycin‐resistant Enterococci (VRE), one of which returned a MIC of 0.5 μg mL−1. Five analogues were found to be equipotent or more potent than the lead 1. Introduction of an indole moiety resulted in the most active robenidine analogue against methicillin‐resistant S. aureus (MRSA), with a MIC of 1.0 μg mL−1. Imine C=NH isosteres (C=O/C=S) were inactive. Monomeric analogues were 16–64 μg mL−1 active against MRSA and VRE. An analogue that lacks the terminal hydrazide NH moiety showed modest Gram‐negative activity at 64 μg mL−1. A 4‐tert‐butyl analogue was shown to be active against both Gram‐positive and ‐negative strains at 16–64 μg mL−1. In general, additional modifications with aromatic moieties was poorly tolerated, except with concomitant introduction of an imine C‐alkyl group. The activity of these analogues against MRSA and VRE ranged from 8 μg mL−1 to inactive (MIC>128 μg mL−1) with the naphthyl and indole analogues. Gram‐negative activity was most promising with two compounds at 16 μg mL−1 against E. coli. Against P. aeruginosa, the highest activity observed was with MIC values of 32 μg mL−1 with another two analogues. Combined, these findings support the further development of the (E)‐2‐benzylidenehydrazine‐1‐carboximidamide scaffold as a promising scaffold for the development of antibiotics against Gram‐positive and Gram‐negative strains.
- 24 January 2018
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (2) , 149-e57
In vitroantimicrobial activity of narasin against common clinical isolates associated with canine otitis externa
Background: Antimicrobial resistance and antimicrobial stewardship are of ever‐increasing importance in veterinary medicine. Re‐purposing of old drugs that are not used in human medicine is one approach that addresses the emergence of multidrug resistance in canine skin and ear infections, and can reduce the use of critically important human antibiotic classes.Hypothesis/Objectives: To determine the antimicrobial activity of narasin, a polyether ionophore conventionally used as a rumen modifier and anticoccidial agent in production animals, against common clinical isolates of canine otitis externa (OE).Animals/Isolates: Clinical isolates (n= 110) from canine OE were tested, including 17 meticillin‐susceptibleStaphylococcus pseudintermedius(MSSP), 13 multidrug‐resistantStaphylococcus pseudintermedius(MDRSP), and 20 each of β‐haemolyticStreptococcusspp.,Pseudomonas aeruginosa,Proteus mirabilisandMalassezia pachydermatis.Methods: Bacterial and yeast isolates were subcultured, suspended in broth and inoculated into 96‐well plates. Organisms were tested against concentrations of narasin ranging from 0.03 to 128 μg/mL. Minimal inhibitory concentrations (MICs) were determined after overnight incubation.Results: NarasinMICs for staphylococcal and streptococcal isolates ranged from 0.06 to 0.25 μg/mL;MIC50andMIC90values for both organisms were 0.125 μg/mL. NoMICs were achieved forPseudomonasorProteusisolates. There was a weak antifungal effect againstM. pachydermatisisolates (MIC32 to >128 μg/mL).Conclusions and Clinical Relevance: Narasin was effective against Gram‐positive bacteria and had antifungal activity at higher concentrations againstM. pachydermatis. However, the lack of Gram‐negative activity would prevent its use as a sole antimicrobial agent in cases of canine OE.
- 24 January 2018
- Published by Wiley in Veterinary Dermatology
- Vol. 29 (2) , 149-e57
In vitroantimicrobial activity of narasin against common clinical isolates associated with canine otitis externa
Background: Antimicrobial resistance and antimicrobial stewardship are of ever‐increasing importance in veterinary medicine. Re‐purposing of old drugs that are not used in human medicine is one approach that addresses the emergence of multidrug resistance in canine skin and ear infections, and can reduce the use of critically important human antibiotic classes.Hypothesis/Objectives: To determine the antimicrobial activity of narasin, a polyether ionophore conventionally used as a rumen modifier and anticoccidial agent in production animals, against common clinical isolates of canine otitis externa (OE).Animals/Isolates: Clinical isolates (n= 110) from canine OE were tested, including 17 meticillin‐susceptibleStaphylococcus pseudintermedius(MSSP), 13 multidrug‐resistantStaphylococcus pseudintermedius(MDRSP), and 20 each of β‐haemolyticStreptococcusspp.,Pseudomonas aeruginosa,Proteus mirabilisandMalassezia pachydermatis.Methods: Bacterial and yeast isolates were subcultured, suspended in broth and inoculated into 96‐well plates. Organisms were tested against concentrations of narasin ranging from 0.03 to 128 μg/mL. Minimal inhibitory concentrations (MICs) were determined after overnight incubation.Results: NarasinMICs for staphylococcal and streptococcal isolates ranged from 0.06 to 0.25 μg/mL;MIC50andMIC90values for both organisms were 0.125 μg/mL. NoMICs were achieved forPseudomonasorProteusisolates. There was a weak antifungal effect againstM. pachydermatisisolates (MIC32 to >128 μg/mL).Conclusions and Clinical Relevance: Narasin was effective against Gram‐positive bacteria and had antifungal activity at higher concentrations againstM. pachydermatis. However, the lack of Gram‐negative activity would prevent its use as a sole antimicrobial agent in cases of canine OE.
- Open Access
- 1 July 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 50 (1) , 125-126
Reverse zoonotic transmission of community-associated MRSA ST1-IV to a dairy cow
- 1 July 2017
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 50 (1) , 125-126
Open AccessReverse zoonotic transmission of community-associated MRSA ST1-IV to a dairy cow